Damoratx
Founded 2025 · 44 employees on LinkedIn · 1 known investors
Find your way into Damoratx
538 people in our graph share verified history with the Damoratx team — schools, employers, funds. One of them is your warm intro.
Ben Robbinsunlockedknows Sherwin Sattarzadeh · together at Harvard Business School (overlapped)
knows the team · via Blueprint Medicines
×8knows the team · via Harvard Business School
×2knows the team · via Questrom School of Business, Boston University
Damora Therapeutics develops targeted monoclonal antibody therapies for rare blood disorders, specifically Essential Thrombocythemia and Myelofibrosis driven by mutant calreticulin mutations. The company is advancing novel subcutaneous biologics to treat approximately 42,000 U.S. patients with these myeloproliferative neoplasms.
Founders & leadership
JJ
Jennifer JarrettinChief Executive Officer & Board Director
SS
Sherwin SattarzadehinChief Operating OfficerSherwin Sattarzadeh is Chief Operating Officer of Damora Therapeutics, bringing over 20 years of experience in biotechnology and pharmaceutical development across multiple therapeutic areas, including roles managing drug development, clinical strategy, and business operations.
BH
Becker HewesChief Medical Officer
Investors · 1
Frequently asked questions
- What does Damoratx do?
- Damora Therapeutics develops targeted monoclonal antibody therapies for rare blood disorders, specifically Essential Thrombocythemia and Myelofibrosis driven by mutant calreticulin mutations. The company is advancing novel subcutaneous biologics to treat approximately 42,000 U.S. patients with these myeloproliferative neoplasms.
- Who are Damoratx's investors?
- Damoratx's investors include TCG Crossover.